NASDAQ:GLMD

Galmed Pharmaceuticals Stock Forecast, Price & News

$3.07

-0.11 (-3.46 %)

(As of 04/16/2021 04:00 PM ET)

Add

Compare

Today's Range

$3.03

Now: $3.07▼

$3.19

50-Day Range

$3.19

MA: $3.56▼

$4.11

52-Week Range

$2.96

Now: $3.07▼

$6.29

Volume279,103 shs

Average Volume380,599 shs

Market Capitalization$77.01 million

P/E RatioN/A

Dividend YieldN/A

Beta2.3

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in ARREST Phase III pivotal study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity, and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a proof-of-concept Phase IIa clinical trial, with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. Galmed Pharmaceuticals Ltd. has a research agreement with Gannex Pharma Co., Ltd. to develop a combination therapy of ASC41 (THR-beta agonist) and Aramchol (SCD 1 inhibitor) for the treatment of NASH; and a research and development collaboration agreement with MyBiotics Pharma Ltd. to identify the selected microbiome repertoire associated with the response to Aramchol. The company was founded in 2000 and is headquartered in Tel Aviv-Yafo, Israel.

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:GLMD

Previous Symbol

CUSIPN/A

CIK1595353

Webwww.galmedpharma.com

Phone972-3693-8448

Employees17

Year FoundedN/A

Debt

Debt-to-Equity RatioN/A

Current Ratio9.81

Quick Ratio9.81

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$2.04 million

Price / Sales37.75

Cash FlowN/A

Price / Cash FlowN/A

Book Value$3.30 per share

Price / Book0.93

Profitability

EPS (Most Recent Fiscal Year)($0.97)

Net Income$-20,460,000.00

Net MarginsN/A

Return on Equity-43.28%

Return on Assets-39.33%

Miscellaneous

Outstanding Shares25,084,000

Market Cap$77.01 million

Next Earnings Date5/13/2021 (Estimated)

OptionableOptionable

Headlines

Zacks: Analysts Anticipate Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) to Post -$0.44 Earnings Per Share
April 7, 2021 | americanbankingnews.com

Galmed Pharmaceuticals (NASDAQ:GLMD) Share Price Crosses Below Two Hundred Day Moving Average of $3.67
April 3, 2021 | americanbankingnews.com

Galmed Pharmaceuticals (NASDAQ:GLMD) PT Lowered to $25.00
March 25, 2021 | americanbankingnews.com

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Given Average Recommendation of "Buy" by Analysts
March 24, 2021 | americanbankingnews.com

Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q4 2020 Results - Earnings Call Transcript
March 20, 2021 | seekingalpha.com

Galmed Dips 2% On Larger-Than-Expected Quarterly Loss
March 19, 2021 | finance.yahoo.com

Galmed Pharmaceuticals: Q4 Earnings Snapshot
March 18, 2021 | finance.yahoo.com

Galmed Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Year End 2020 Financial Results
March 18, 2021 | finance.yahoo.com

Galmed Pharmaceuticals Announces Dosing of First Subject in First in Human Phase 1 Trial of Amilo-5MER
March 16, 2021 | finance.yahoo.com

Galmed Pharmaceuticals to Report Fourth Quarter and Year End 2020 Financial Results and Provide Business Update on Thursday March 18
March 11, 2021 | finance.yahoo.com

Galmed Pharmaceuticals Announces Proposed Offering of Ordinary Shares
February 16, 2021 | finance.yahoo.com

Galmed Pharmaceuticals Announces Pricing of $10 Million Public Offering of Ordinary Shares
February 16, 2021 | finance.yahoo.com

These 2 Penny Stocks Could Rack up Triple-Digit Gains, Say Analysts
February 11, 2021 | finance.yahoo.com

Are Institutions Heavily Invested In Galmed Pharmaceuticals Ltd.'s (NASDAQ:GLMD) Shares?
February 4, 2021 | finance.yahoo.com

Galmed Pharmaceuticals Announces Upcoming Publication in JHEP Reports of New Data Supporting Aramchol's Novel Anti-Fibrotic Mechanism of Action
January 26, 2021 | finance.yahoo.com

Galmed Hosting KOL Symposium and Pipeline Update
January 19, 2021 | finance.yahoo.com

Is Galmed Pharmaceuticals Ltd (GLMD) A Good Stock To Buy?
December 4, 2020 | finance.yahoo.com

Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q3 2020 Results - Earnings Call Transcript
November 12, 2020 | seekingalpha.com

Galmed Pharmaceuticals Ltd. to Host Earnings Call
November 12, 2020 | finance.yahoo.com

Galmed Pharmaceuticals Reports Third Quarter 2020 Financial Results
November 12, 2020 | finance.yahoo.com

See More Headlines

MarketRank^™

Overall MarketRank^™

1.46 out of 5 stars

Medical Sector

576th out of 2,021 stocks

Pharmaceutical Preparations Industry

271st out of 772 stocks

3.4 Analyst's Opinion

Consensus Rating
Galmed Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.71, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $18.14, Galmed Pharmaceuticals has a forecasted upside of 491.0% from its current price of $3.07.
Amount of Analyst Coverage
Galmed Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

3.3 Community Rank

Outperform Votes
Galmed Pharmaceuticals has received 437 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Galmed Pharmaceuticals has received 233 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Galmed Pharmaceuticals has received 65.22% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Galmed Pharmaceuticals and other stocks. Vote “Outperform” if you believe GLMD will outperform the S&P 500 over the long term. Vote “Underperform” if you believe GLMD will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Galmed Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Galmed Pharmaceuticals does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Galmed Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Institutions
Only 31.53% of the stock of Galmed Pharmaceuticals is held by institutions.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Galmed Pharmaceuticals are expected to decrease in the coming year, from ($1.27) to ($1.49) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Galmed Pharmaceuticals is -2.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Galmed Pharmaceuticals is -2.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Galmed Pharmaceuticals has a P/B Ratio of 0.93. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

$3.07

-0.11 (-3.46 %)

(As of 04/16/2021 04:00 PM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive GLMD News and Ratings via Email

Sign-up to receive the latest news and ratings for GLMD and its competitors with MarketBeat's FREE daily newsletter.

Galmed Pharmaceuticals (NASDAQ:GLMD) Frequently Asked Questions

Is Galmed Pharmaceuticals a buy right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Galmed Pharmaceuticals in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Galmed Pharmaceuticals stock.
View analyst ratings for Galmed Pharmaceuticals or view top-rated stocks.

What stocks does MarketBeat like better than Galmed Pharmaceuticals?

Wall Street analysts have given Galmed Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Galmed Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Galmed Pharmaceuticals?

Galmed Pharmaceuticals saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 288,300 shares, an increase of 30.2% from the March 15th total of 221,500 shares. Based on an average daily volume of 404,400 shares, the short-interest ratio is currently 0.7 days. Currently, 1.5% of the company's stock are sold short.
View Galmed Pharmaceuticals' Short Interest.

When is Galmed Pharmaceuticals' next earnings date?

Galmed Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, May 13th 2021.
View our earnings forecast for Galmed Pharmaceuticals.

How were Galmed Pharmaceuticals' earnings last quarter?

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) announced its quarterly earnings results on Wednesday, March, 17th. The biopharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.36) by $0.12.
View Galmed Pharmaceuticals' earnings history.

How has Galmed Pharmaceuticals' stock price been impacted by Coronavirus?

Galmed Pharmaceuticals' stock was trading at $4.21 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, GLMD stock has decreased by 27.1% and is now trading at $3.07.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for GLMD?

7 equities research analysts have issued 12 month price targets for Galmed Pharmaceuticals' stock. Their forecasts range from $8.00 to $33.00. On average, they anticipate Galmed Pharmaceuticals' stock price to reach $18.14 in the next year. This suggests a possible upside of 491.0% from the stock's current price.
View analysts' price targets for Galmed Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Galmed Pharmaceuticals' key executives?

Galmed Pharmaceuticals' management team includes the following people:

Mr. Allen Baharaff, Co-Founder, CEO, Pres & Director (Age 56, Pay $784.86k)
Mr. Yohai Stenzler, CFO & Controller (Age 38, Pay $155.34k)
Mr. Guy Nehemya, Chief Operating Officer (Age 36, Pay $165.43k)
Dr. Liat Hayardeny, Chief Scientific Officer (Age 54, Pay $242.52k)
Dr. Tali Gorfine, Chief Medical Officer (Age 51, Pay $242.28k)
Ms. Yael Hollander, VP of Legal Affairs & Strategy (Age 38)

Who are some of Galmed Pharmaceuticals' key competitors?

Some companies that are related to Galmed Pharmaceuticals include Wave Life Sciences (WVE), Ampio Pharmaceuticals (AMPE), Immunic (IMUX), Trevena (TRVN), CymaBay Therapeutics (CBAY), CorMedix (CRMD), Arbutus Biopharma (ABUS), VistaGen Therapeutics (VTGN), Sol-Gel Technologies (SLGL), Immunome (IMNM), TFF Pharmaceuticals (TFFP), Theratechnologies (THERF), Kezar Life Sciences (KZR), Kamada (KMDA) and VYNE Therapeutics (VYNE).
View all of GLMD's competitors.

What other stocks do shareholders of Galmed Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Galmed Pharmaceuticals investors own include OPKO Health (OPK), Viking Therapeutics (VKTX), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Rite Aid (RAD), Exelixis (EXEL), Ocular Therapeutix (OCUL), TG Therapeutics (TGTX), TherapeuticsMD (TXMD) and Corbus Pharmaceuticals (CRBP).

What is Galmed Pharmaceuticals' stock symbol?

Galmed Pharmaceuticals trades on the NASDAQ under the ticker symbol "GLMD."

How do I buy shares of Galmed Pharmaceuticals?

Shares of GLMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Galmed Pharmaceuticals' stock price today?

One share of GLMD stock can currently be purchased for approximately $3.07.

How much money does Galmed Pharmaceuticals make?

Galmed Pharmaceuticals has a market capitalization of $77.01 million and generates $2.04 million in revenue each year. The biopharmaceutical company earns $-20,460,000.00 in net income (profit) each year or ($0.97) on an earnings per share basis.

How many employees does Galmed Pharmaceuticals have?

Galmed Pharmaceuticals employs 17 workers across the globe.

What is Galmed Pharmaceuticals' official website?

The official website for Galmed Pharmaceuticals is www.galmedpharma.com.

Where are Galmed Pharmaceuticals' headquarters?

Galmed Pharmaceuticals is headquartered at 16 TIOMKIN STREET, TEL AVIV L3, 6578317.

How can I contact Galmed Pharmaceuticals?

Galmed Pharmaceuticals' mailing address is 16 TIOMKIN STREET, TEL AVIV L3, 6578317. The biopharmaceutical company can be reached via phone at 972-3693-8448 or via email at [email protected]

This page was last updated on 4/16/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here